Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

South Korea's top court clears SK Bioscience’s vaccine of patent violation, unlocking export potential and global market ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The Sport Impact Summit (SIS) has announced two major strategic partnerships with Scoreboard, sport’s leading AI-powered ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

The two platforms offer public and private sector organisations ready-to-deploy tools for both reporting and storytelling — ...

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, ...

Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a Strong Buy despite market doubts.

The Global Vaccine Storage Equipment Market is expected to grow at a rate of 8-10% by 2026. Rising number of infectious diseases and immunological disorders, large-scale implementation of vaccination ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...